| A module of negative feedback regulators defines growth factor signaling I Amit, A Citri, T Shay, Y Lu, M Katz, F Zhang, G Tarcic, D Siwak, J Lahad, ... Nature genetics 39 (4), 503-512, 2007 | 612 | 2007 |
| The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression E Shema, I Tirosh, Y Aylon, J Huang, C Ye, N Moskovits, N Raver-Shapira, ... Genes & development 22 (19), 2664-2676, 2008 | 307 | 2008 |
| Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ... Cancer discovery 6 (12), 1352-1365, 2016 | 234 | 2016 |
| A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration M Katz, I Amit, A Citri, T Shay, S Carvalho, S Lavi, F Milanezi, L Lyass, ... Nature cell biology 9 (8), 961-969, 2007 | 225 | 2007 |
| An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis G Tarcic, SK Boguslavsky, J Wakim, T Kiuchi, A Liu, F Reinitz, ... Current Biology 19 (21), 1788-1798, 2009 | 143 | 2009 |
| EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors R Avraham, A Sas-Chen, O Manor, I Steinfeld, R Shalgi, G Tarcic, ... Science signaling 3 (124), ra43-ra43, 2010 | 128 | 2010 |
| MHC class I-independent recognition of NK-activating receptor KIR2DS4 G Katz, R Gazit, TI Arnon, T Gonen-Gross, G Tarcic, G Markel, R Gruda, ... The Journal of Immunology 173 (3), 1819-1825, 2004 | 124 | 2004 |
| EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF G Tarcic, R Avraham, G Pines, I Amit, T Shay, Y Lu, Y Zwang, M Katz, ... The FASEB Journal 26 (4), 1582, 2012 | 108 | 2012 |
| SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors L Roth, S Srivastava, M Lindzen, A Sas-Chen, M Sheffer, M Lauriola, ... Science signaling 11 (515), eaan0949, 2018 | 53 | 2018 |
| Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer N Peled, LC Roisman, B Miron, R Pfeffer, RB Lanman, M Ilouze, A Dvir, ... Journal of Thoracic Oncology 12 (7), e81-e84, 2017 | 53 | 2017 |
| Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016; 6: 1352 … DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ... DOI: https://doi. org/10.1158/2159-8290. CD-16-0050. PMID: https://www. ncbi …, 0 | 40 | |
| Navigator‐3, a modulator of cell migration, may act as a suppressor of breast cancer progression H Cohen‐Dvashi, N Ben‐Chetrit, R Russell, S Carvalho, M Lauriola, ... EMBO molecular medicine 7 (3), 299-314, 2015 | 36 | 2015 |
| Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma N Jin, B Keam, J Cho, MJ Lee, HR Kim, H Torosyan, N Jura, PKS Ng, ... The Journal of clinical investigation 131 (22), 2021 | 25 | 2021 |
| CRISPR-Directed In Vitro Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract BM Sansbury, AM Wagner, E Nitzan, G Tarcic, EB Kmiec The CRISPR journal 1 (2), 191-202, 2018 | 22 | 2018 |
| CRISPR-Directed Gene Editing Catalyzes Precise Gene Segment Replacement In Vitro Enabling a Novel Method for Multiplex Site-Directed Mutagenesis BM Sansbury, AM Wagner, G Tarcic, S Barth, E Nitzan, R Goldfus, ... The CRISPR Journal 2 (2), 121-132, 2019 | 19 | 2019 |
| Clinical and functional characterization of atypical KRAS/NRAS mutations in metastatic colorectal cancer JM Loree, Y Wang, MA Syed, AV Sorokin, O Coker, J Xiu, BA Weinberg, ... Clinical Cancer Research 27 (16), 4587-4598, 2021 | 18 | 2021 |
| Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort SR Fairclough, LA Kiedrowski, JJ Lin, O Zelichov, G Tarcic, ... Experimental hematology & oncology 8 (1), 24, 2019 | 17 | 2019 |
| ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype N Ben-Chetrit, G Tarcic, Y Yarden Cell adhesion & migration 7 (1), 33-37, 2013 | 15 | 2013 |
| Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations. JM Loree, B Miron, V Holla, MJ Overman, AAL Pereira, M Lam, VK Morris, ... Journal of Clinical Oncology 35 (15_suppl), 3589-3589, 2017 | 13 | 2017 |
| MAP Kinase activation by receptor tyrosine kinases: in control of cell migration G Tarcic, Y Yarden MAP Kinase Signaling Protocols: Second Edition, 125-135, 2010 | 13 | 2010 |
